Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak

In the context of quarantine with COVID-19, we wish to study the experience and psychological impact in adult patients living with osteoporosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sars-CoV2 Bone Diseases Bone Diseases, Metabolic COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Metabolic Diseases Musculoskeletal Diseases Nidovirales Infections Nutritional and Metabolic Diseases Osteoporosis Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hopital Roger Salengro, CHU Lille

Lille, 59037, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient with osteoporosis
Patient in confinement
Patient with sufficient understanding of the French language

Exclusion criteria

Non adult patient
patient without quarantine

Treatment and study plan

questionnaire assesment

Other

questionnaire assesment

Primary outcomes

percentage of patient with feeling of disabilities

Time frame: maximum 1 week from baseline on

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Acronym: OsPsyCOVID

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Apr 17, 2020
Registry last updated: Dec 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed